{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:52:26Z","timestamp":1783702346783,"version":"3.55.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kunming Health Care Commission's Health Research Project","award":["2023-13-01-017"],"award-info":[{"award-number":["2023-13-01-017"]}]},{"name":"The Scientific Research Fund Project of the Yunnan Provincial Department of Education","award":["2024J0371"],"award-info":[{"award-number":["2024J0371"]}]},{"name":"Yunnan Provincial Association of Pharmacists in Healthcare Facilities Scientific Research Special Fund Project","award":["2024YSXH06"],"award-info":[{"award-number":["2024YSXH06"]}]},{"name":"Thousand Project Programme of kunming health Science and Technology Talent Cultivation","award":["2023-SW (back-up)-84"],"award-info":[{"award-number":["2023-SW (back-up)-84"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>Brentuximab Vedotin (BV) is a novel antibody-drug conjugate (ADC) approved for the treatment of classical Hodgkin\u2019s lymphoma and systemic anaplastic large cell lymphoma. However, as a relatively new therapeutic agent, the long-term safety profile and adverse event (AE) profile of BV require further investigation. This study aimed to identify significant and unexpected AEs associated with BV using data from the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) databases.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Data on BV-related AEs were extracted from the FAERS and JADER databases. Signal detection was performed using the reporting odds ratio (ROR) and 95% confidence intervals (95% CI). Risk signals were categorized according to system organ classes (SOCs) and preferred terms (PTs) as defined by the Medical Dictionary for Regulatory Activities (MedDRA) version 26.0. In addition, the onset times of BV-related AEs were analyzed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Between 2004 and 2023, a total of 19,279 and 2,561 AEs related to BV were recorded in the FAERS and JADER databases, respectively. At the SOC level, prominent signals in the FAERS database included blood and lymphatic system disorders, benign, malignant, and unspecified neoplasms (including cysts and polyps), as well as congenital, familial, and genetic disorders. In the JADER database, the most notable signals involved benign, malignant, and unspecified neoplasms, blood and lymphatic system disorders, and nervous system disorders. At the PT level, the top five signals in the FAERS database were peripheral motor neuropathy, peripheral sensory neuropathy, pneumocystis jirovecii pneumonia, febrile bone marrow aplasia, and polyneuropathy. Unexpected AEs included febrile bone marrow aplasia and Guillain-Barr\u00e9 syndrome. In the JADER database, the top five signals included peripheral motor neuropathy, peripheral sensory neuropathy, bacterial gastroenteritis, febrile neutropenia and pneumonia, with unexpected AEs such as left ventricular dysfunction, cardiomegaly, retinal detachment, and marasmus. The median onset time of AEs was 22 days (interquartile range [IQR] 7\u201381 days) in FAERS and 27 days (IQR 7\u201373 days) in JADER.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The signal detection results from the FAERS and JADER databases highlight the importance of monitoring significant and unexpected AEs associated with BV, particularly in the early stages of treatment. These findings contribute to enhancing the post-marketing safety profile of BV and offer valuable insights for clinical risk management strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0322378","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T17:25:05Z","timestamp":1747416305000},"page":"e0322378","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases"],"prefix":"10.1371","volume":"20","author":[{"given":"Feilong","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6012-0430","authenticated-orcid":true,"given":"Hongying","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"1","key":"pone.0322378.ref001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Z Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"pone.0322378.ref002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-022-05054-9","article-title":"Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives","volume":"102","author":"HM Prince","year":"2023","journal-title":"Ann Hematol"},{"issue":"21","key":"pone.0322378.ref003","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"RA de Claro","year":"2012","journal-title":"Clin Cancer Res"},{"key":"pone.0322378.ref004","author":"Vedotin","year":"2023"},{"issue":"6","key":"pone.0322378.ref005","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/1078-0432.CCR-18-2435","article-title":"Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma","volume":"25","author":"R Ramchandren","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10168","key":"pone.0322378.ref006","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"S Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"pone.0322378.ref007","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"KEYNOTE-204 investigators","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"pone.0322378.ref008","first-page":"512","article-title":"Safety profile of brentuximab vedotin in Japanese patients with relapsed\/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study","volume":"22","author":"K Izutsu","year":"2021","journal-title":"Int J Hematol"},{"issue":"4","key":"pone.0322378.ref009","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-251867","article-title":"Severe insulin resistance in a patient with diabetes after treatment with brentuximab vedotin","volume":"17","author":"G Peeters","year":"2024","journal-title":"BMJ Case Rep"},{"key":"pone.0322378.ref010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/JBM.S444004","article-title":"Severe Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis (HLH)-Like Syndrome Following Administration of Combined Brentuximab Vedotin and Nivolumab for Recurrent Classical Hodgkin Lymphoma: A Case Report","volume":"15","author":"O Mosalem","year":"2024","journal-title":"J Blood Med"},{"key":"pone.0322378.ref011","doi-asserted-by":"crossref","first-page":"1610445","DOI":"10.3389\/pore.2022.1610445","article-title":"Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review","volume":"28","author":"E Truszkowska","year":"2022","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"pone.0322378.ref012","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s13410-022-01116-w","article-title":"Brentuximab vedotin-associated diabetic ketoacidosis: a case report","volume":"43","author":"D K\u00f6ksalan","year":"2023","journal-title":"Int J Diabetes Dev Ctries"},{"key":"pone.0322378.ref013","doi-asserted-by":"crossref","first-page":"102393","DOI":"10.1016\/j.ctrv.2022.102393","article-title":"A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)","volume":"106","author":"Z Abuhelwa","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"pone.0322378.ref014","doi-asserted-by":"crossref","first-page":"20420986241260211","DOI":"10.1177\/20420986241260211","article-title":"Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System","volume":"15","author":"M Ouyang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"pone.0322378.ref015","doi-asserted-by":"crossref","first-page":"1392914","DOI":"10.3389\/fphar.2024.1392914","article-title":"A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases","volume":"15","author":"S Zou","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0322378.ref016","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/s41598-022-06611-y","article-title":"Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER","volume":"12","author":"T Imai","year":"2022","journal-title":"Sci Rep"},{"key":"pone.0322378.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2376686","article-title":"Data mining study on adverse events of tirzepatide based on FAERS database","volume":"15","author":"Y Huo","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0322378.ref018","doi-asserted-by":"crossref","first-page":"1039867","DOI":"10.3389\/fphar.2022.1039867","article-title":"Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database","volume":"13","author":"J Zhou","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"pone.0322378.ref019","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"pone.0322378.ref020","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"SM Ansell","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"pone.0322378.ref021","first-page":"741","article-title":"Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)","volume":"45","author":"Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association; Expert Committee for Monitoring the Clinical Application of Antitumor Drugs; Breast Cancer Expert Committee of National Cancer Quality Control Center; Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center","year":"2023","journal-title":"Chin J Oncol"},{"issue":"23","key":"pone.0322378.ref022","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"SM Horwitz","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"pone.0322378.ref023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"JC Masters","year":"2018","journal-title":"Invest New Drugs"},{"issue":"10","key":"pone.0322378.ref024","doi-asserted-by":"crossref","first-page":"107778","DOI":"10.1016\/j.isci.2023.107778","article-title":"Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates","volume":"26","author":"Z Fu","year":"2023","journal-title":"iScience"},{"issue":"23","key":"pone.0322378.ref025","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy","volume":"13","author":"R Velasco","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"pone.0322378.ref026","first-page":"449","article-title":"Chinese expert consensus on principles for clinical practice of brentuximab vedotin in CD30-positive lymphoma (2022 version)","volume":"31","author":"Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO)","year":"2022","journal-title":"Journal of Leukemia & Lymphoma"},{"issue":"16","key":"pone.0322378.ref027","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"KR Carson","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"pone.0322378.ref028","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"S Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"pone.0322378.ref029","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00157-6","article-title":"Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1\/2 trial","volume":"10","author":"PG Rubinstein","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"pone.0322378.ref030","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1080\/10428194.2019.1579321","article-title":"Acute liver injury leading to death in the setting of brentuximab vedotin monotherapy","volume":"60","author":"J Neeman","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"pone.0322378.ref031","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"NL Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"1","key":"pone.0322378.ref032","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: A multicentre retrospective study","volume":"200","author":"T Shragai","year":"2023","journal-title":"Br J Haematol"},{"key":"pone.0322378.ref033","doi-asserted-by":"crossref","first-page":"1419145","DOI":"10.3389\/fonc.2024.1419145","article-title":"Insights into uveitis from Brentuximab vedotin in refractory Hodgkin\u2019s lymphoma: a case report and brief review","volume":"14","author":"M Liu","year":"2024","journal-title":"Front Oncol"},{"issue":"09","key":"pone.0322378.ref034","first-page":"985","article-title":"Research progress of drug-induced ocular toxicity of antibody-drug conjugate","volume":"32","author":"F Xia","year":"2023","journal-title":"Chin J Pharmacoepidemiol"},{"issue":"7","key":"pone.0322378.ref035","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/jnnp-2020-323124","article-title":"Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies","volume":"91","author":"G Fargeot","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0322378.ref036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"F Leroy","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"pone.0322378.ref037","first-page":"254","article-title":"Literature analysis of adverse drug reactions of brentuximab","volume":"9","author":"Z Fu","year":"2022","journal-title":"Chinese Journal of Drug Application and Monitoring"},{"issue":"15","key":"pone.0322378.ref038","article-title":"Literature review and analysis of adverse drug reactions of brentuximab vedotin","volume":"32","author":"M Lv","journal-title":"Chinese Journal of New Drugs"},{"key":"pone.0322378.ref039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2416917","article-title":"Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases","volume":"15","author":"Q Liang","year":"2024","journal-title":"Expert Opin Drug Saf"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T17:25:15Z","timestamp":1747416315000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322378"}},"subtitle":[],"editor":[{"given":"Mehmet","family":"Baysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0322378","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}